We performed gene expression profiling in bladder cancer patients to identify cancerspecific survival-related genes in muscle invasive bladder cancer (MIBC) patients. Sixty-two patients with MIBC were selected as the original cohort and another 118 MIBC patients were chosen as a validation cohort. The expression of USP18, DGCR2, and ZNF699 genes were measured and we analyzed the association between gene signatures and survival. USP18 and DGCR2, were significantly correlated to cancer-specific death (P = 0.020, P = 0.007, respectively). Cancer-specific survival in the low USP18 or DGCR2 expression group was significantly longer than the high expression group (P = 0.018, P = 0.006, respectively). In multivariate Cox regression analysis, a combination of USP18 and DGCR2 mRNA expression levels were significant risk factors for cancer-specific death (HR, 2.106; CI, 1.043-4.254, P = 0.038). Overall survival and cancer-specific survival rates in the lowcombination group were significantly longer than those in the high-expression group (P = 0.001, both). In conclusion, decreased expressions of USP18 and DGCR2 were significantly associated with longer cancer-specific survival, and also the combination of two genes was correlated to a longer survival for MIBC patients. Thus, the combination of USP18 and DGCR2 expression was shown to be a reliable prognostic marker for cancerspecific survival in MIBC.
INTRODUCTION
In the USA, more than 70,000 new cases of bladder cancer were diagnosed and at least 14,000 patients died from bladder can cer (1) . Almost 25% of newly diagnosed patients have muscle invasive bladder cancer (MIBC) and nearly 50% of these pati ents already have occult distant metastases at the time of diag nosis. The standard mode of treatment for MIBC is radical cys tectomy. However, despite improvement in surgical techniques, 5yr diseasefree survival after radical cystectomy remains be tween 55% and 65% (2, 3) . The reason for such a low 5yr sur vival rate for radical cystectomy is presumably due to clinical understaging and micrometastasis (4) .
Stage and grade are well established predictors for survival in MIBC (5) . Hence, clinicians have usually used these parameters for counseling of patients and decision of treatment. However, despite the same treatment, there are differences in survival out comes for patients with the same stages and grades. Therefore, various studies for molecular markers have attempted to im prove the survival rates and predicted outcomes.
Recently, interest has grown in the use of microarraybased gene expression profiling for predicting the survival and out comes for individual cancer patients (6) . Highthroughput mi croarray technology can be used to investigate the RNA expres sion levels of hundreds of thousands of genes, and it can pro vide comprehensive insight for molecular levels of human can cer (7) . Using this technology, numerous genetic markers have been found and validated as diagnostic and prognostic indica tors. Already, microarraybased breast cancer analysis is a use ful tool in predicting the response to hormonal treatment, the response to target therapy, and in estimating survival for breast cancer patients (8) . For cases of MIBC, however, there have been only a few reports of the use of microarrays to successfully pre dict survival rates (9) .
In a previous study, we investigated gene expression profiling in bladder cancer patients, and uploaded the full microarray data set at http://www.ncbi.nlm.nih.gov/geo/ with the data se ries accession number GSE13507. Using this data, we selected 3 
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MATERIALS AND METHODS
Bladder cancer micro-array data Microarray geneexpression profiling techniques have been described in previous reports (10) . Briefly, we used 165 primary bladder cancer samples, 23 recurrent nonmuscle invasive tu mor tissues, 58 normalappearing bladder mucosa surround ing cancer, and 10 normal bladder mucosa for microarray anal ysis. Unsupervised hierarchical clustering analysis was used to stratify the prognosisrelated gene classifiers. The full microar ray data set is available online at http://www.ncbi.nlm.nih.gov/ geo/ under the data series accession number GSE13507.
Patients and tissue samples
Sixtytwo patients with MIBC were selected by microarray pro filing (original cohort). We collected new tumor specimens from 118 MIBC patients with histologically verified urothelial cell carcinoma (UCC) as a validation cohort. To reduce confound ing factors affecting the analyses, and to delineate a more ho mogenous study population, we excluded patients diagnosed with a concomitant carcinoma in situ (CIS), or for whom data collection was incomplete. All tumors were macrodissected, typically within 15 min of surgical resection. Each bladder can cer specimen was confirmed by pathological analysis of a part of the tissue sample in freshfrozen sections from cystectomy and transurethral resection (TUR) specimens, then frozen in liquid nitrogen and stored at 80°C until use.
Tumors were staged and graded according to the 2002 TNM classification and the 1973 WHO grading system, respectively (11, 12) . Patients with localized or locally advanced tumors and good ECOG performance status (0 or 1) underwent radical cys tectomy and complete pelvic lymph node dissection. Patients who were not eligible for radical cystectomy due to metastatic disease, poor life expectancy, or poor ECOG performance sta tus ( = 2) underwent TUR for histopathological diagnosis. Pa tients with pT3, pT4 or nodepositive disease based on the anal ysis of radical cystectomy specimens, or with metastatic disease but good performance status, received at least four cycles of cis platinbased chemotherapy. Each patient was followed and ma naged according to standard protocol (13) .
RNA extraction and construction of cDNA Total RNA was isolated from tissue using 1 mL of TRIzol (Invit rogen, Carlsbad, CA, USA) and homogenization in a 5 mL glass tube. The homogenate was transferred to a 1.5 mL tube and was mixed with 200 µL chloroform. After incubation for 5 min at 4°C, the homogenate was centrifuged for 13 min at 13,000 g and 4°C. The upper aqueous phase was transferred to a clean tube and 500 µL isopropanol was added, followed by incubation for 60 min at 4°C. The tube was then centrifuged for 8 min at 13,000 g and 4°C. Then, the upper aqueous phase was removed, mixed with 500 µL of 75% ethanol, and centrifuged for 5 min at 13,000 g and 4°C. After the upper aqueous layer was discarded, the pel let was dried at room temperature, dissolved with diethylpyro carbonate (DEPC)treated water, and stored at 80°C. The qual ity and integrity of the RNA were confirmed by agarose gel elec trophoresis and ethidium bromide staining, followed by visual examination under ultraviolet light. cDNA was then prepared from 1 µg of total RNA using a FirstStrand cDNA Synthesis Kit (Clontech, TAKARA, Otsu, Japan) according to the manufactur er's protocol.
Real-time PCR
To quantify the mRNA expression levels, realtime PCR amplifi cation was performed using a Rotor Gene 6000 instrument (Cor bett Research, Mortlake, Australia). Realtime PCR assays using SYBR Premix EX Taq (TAKARA BIO INC., Otsu, Japan) were car ried out in microreaction tubes (Corbett Research). Primers were used to amplify USP18, DGCR2, and ZNF699. PCR reac tion was performed in a final volume of 10 µL, consisting of 5 µL of 2 × SYBR premix EX Taq buffer, 0.5 µL each of 5´ and 3´ primer (10 pM/µL), and 2 µL of the sample cDNA. The product was purified with a QIAquick Extraction kit (QIAGEN, Hilden, Germany), quantified with a spectrometer (Perkin Elmer MBA 2000, Fremont, CA, USA), and sequenced with an automated laser fluorescence sequencer (ABI PRISM 3100 Genetic Ana lyzer, Foster City, CA, USA). The known concentration of the product was 10fold serially diluted from 100 pg/µL to 0.1 pg/ µL. The dilution series of PCR products was used for establish ing the standard curve of realtime PCR. The realtime PCR con ditions were 1 cycle at 96°C for 20 sec, followed by 40 cycles of 3 sec at 96°C for denaturation, 15 sec at 60°C for annealing, and 15 sec at 72°C for extension. The melting program was perform ed at 7295°C with a heating rate of 1°C per 45 sec. Spectral data were captured and analyzed using RotorGene RealTime Anal ysis Software 6.0 Build 14 (Corbett Research). All samples were run in triplicate. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was applied as an endogenous RNA reference gene. Gene expression was normalized to the expression of GAPDH.
Statistical analysis
To normalize the highly skewed distribution of the mRNA ex pression of each gene, the data were naturallog transformed and then backtransformed for an interpretation of the results. The association between cancerspecific survival and the gene signatures was evaluated using univariate Cox regression analy sis. Cancerspecific and overall survival was calculated accord http://dx.doi.org/10.3346/jkms.2014. 29.3.351 ing to the KaplanMeier method, with differences between the times assessed using logrank statistics. After univariate Cox analysis of the three candidate genes, two were used to calcu late a risk score of cancerspecific death for each patient, de fined as the sum of the levels of expression of each gene multi plied by the corresponding regression coefficient (14, 15) . Re ceiver operating characteristic (ROC) curves were used to iden tify the optimal cutoff point of each risk score that yielded the highest combined sensitivity and specificity for cancerspecific survival. Based on these values, patients were classified into ei ther a goodprognostic or a poorprognostic gene signature group. The prognostic value of the combination of gene expres sion was determined by univariate and multivariate Cox pro portional hazard regression models. Statistical analyses were performed using SPSS ver. 19.0 (SPSS Inc., Chicago, IL, USA), and P values of less than 0.05 were considered statistically sig nificant.
Ethics statement
The study protocol was approved by the institutional review board of Chungbuk National University (IRB approved number 200601001). Informed consent was obtain ed from each sub ject.
The biospecimens for this study were provided by the Chun gbuk National University Hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs. All samples derived from the Nation al Biobank of Korea were obtained with informed consent un der institutional review boardapproved protocols.
RESULTS
Cancer-specific survival-related gene classifiers
In microarray analysis, we chose 21 candidate genes that showed highly significant differences between low and high mRNA ex pression groups in 62 patients with MIBC. And then, candidate genes were selected using KaplanMeier analysis and a log rank test (P < 0.01, respectively). Finally, 3 candidate genes (USP18, DGCR2, ZNF699) were selected (P = 0.002, P = 0.008, and P = 0.002, respectively).
Baseline characteristics
The mean age of the 118 subjects with primary MIBC was 67.3 (3887) yr, and the median followup period was 16.9 (2.1180.9) months. Eighteen patients (15.3%) had metastases. Other base line characteristics of the patients are presented in Table 1 .
Identification of genes associated with cancer-specific death in MIBC patients
Univariate Cox regression analysis was performed for three genes (USP18, DGCR2, ZNF699), which were previously selected by microarray analysis. Two of them, USP18 and DGCR2, were significantly correlated to cancerspecific death (P = 0.020, P = 0.007, respectively). Cancerspecific survival was significantly different between the high and low USP18 or DGCR2 mRNA expression groups, in that cancerspecific survival in the low USP18 or DGCR2 expression group was significantly longer than that in the high expression group (P = 0.018, P = 0.006, re spectively) (Fig. 1) . Also, overall survival in the low USP18 or DGCR2 expression group was significantly longer than that in the high expression group (P = 0.015, P = 0.008, respectively) (Fig. 2 ).
USP18 and DGCR2 mRNA expression level according to clinicopathological parameters
The mRNA expression of USP18 was significantly higher in pa tients with lymph node involvement (P < 0.001) or grade 3 (P = 0.013). The mRNA expression of DGCR2 was significantly high er in patients with lymph node involvement (P = 0.034) ( Table  2 ). There were no significant differences between USP18 and DGCR2 for other clinicopathological parameters such as T stage and M stage.
The value of the combination of USP18 and DGCR2 mRNA expression level as a prognostic marker for cancerspecific survival These two genes were then used to calculate a risk score for cancerspecific death in MIBC patients. The risk score identi fied two groups of patients. A goodprognostic signature group represented relatively low expression levels of the two genes, while a poorprognostic signature group had a significantly high er expression. Using a ROC curve, a cutoff value (46.6093) was determined for cancerspecific death with the highest combin ed sensitivity (77.6%) and specificity (50.0%). In univariate Cox regression analysis of clinicopathological variables, age, T4, pos itive lymph node, metastasis, and a combination of USP18 and DGCR2 mRNA expression levels were significant risk factors for cancerspecific death (P = 0.035, P = 0.005, P = 0.011, P = 0.006, and P = 0.001, respectively). In multivariate Cox regression anal ysis, T4, metastasis, chemotherapy, and a combination of USP18 and DGCR2 mRNA expression levels were significant prognos tic factors for cancerspecific death (HR, 2.587; CI, 1.3574.933, P = 0.004; HR, 2.376; CI, 1.1604.866, P = 0.018; HR,0.459; CI, 0.2400.875, P = 0.018, and HR, 2.106; CI, 1.0434.254, P = 0.038, respectively) ( Table 3) . Overall survival and cancerspecific sur vival in the low expression group was significantly longer than that in the high expression group (P = 0.001, both) ( Fig. 1C and Fig. 2C ).
DISCUSSION
In the present study, the combined expressions of USP18 and DGCR2 were used to predict cancerspecific survival in patients with MIBC, which was reconfirmed by validation in different cohorts. In MIBC, pathological tumor characteristics such as lymph node involvement, tumor stage, grade, and histological subtype have been established as significant predictors of out comes (16) . Also, clinical factors such as time from diagnosis to surgery, patient age, and gender are considered to be important predictors of outcome (16) . To improve the accuracy of predict ing outcomes, several nomograms that include pathological tu mor characteristics and clinical factors have been used (17, 18) . However, the heterogeneity of the biological behaviors of tu mors may limit the accuracy of predicting the outcome of no mograms based on clinical and pathological characteristics. Accordingly, there is growing interest in a molecular biomarker for predicting tumor aggressiveness and patient outcomes. p53 expression has been associated with tumor stage, grade, lymph node metastasis, and cancerspecific death (19) . Also, p27 and Ki67 could be used as predictive markers for recurrence and survival in MIBC patients who have undergone radical cystec tomy (19) . Bcl2, caspase3 and survivin were found to be asso ciated with grade, stage, metastasis, and survival (20) . Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF) and thrombospondin1 have been used as independent predictors of clinical outcomes in bladder cancer patients (21, 22) . However, a single molecular biomarker cannot reflect tu mor biology due to the complexity of tumorigenesis. Therefore, the trend for predicting prognostic value has changed to the si multaneous assessment of multiple biomarkers in cancer pa tients (23) . Similarly, this study was carried out to predict out comes after the assessment of 2 biomarkers (USP18 and DGCR2) in MIBC. Ubiquitin specific peptidase 18 (USP18) is a cysteine protease that is known to remove interferon stimulated gene 15 (ISG15), a ubiquitinlike protein family member, from conjugated pro teins (24, 25) . Duex et al. (26) reported that USP18 regulates epidermal growth factor Receptor (EGFR) expression and can cer cell survival. Inhibition of USP18 reduces the levels of EGFR and other oncogenic proteins and inhibits the tumorigenic ac tivity of cancer cells. Interestingly, in bladder cancer, elevated EGFR expression has been strongly associated with a decrease in the rate of relapsefree survival (27) . Certainly, low USP18 re duced the levels of EGFR and inhibited the tumorigenic activity of cancer cells, and then, increased the survival of cancer pati ents. In the present study, we also demonstrated that compared with a high expression group, a low USP18 expression group was indicative of significantly longer rates of overall and cancer specific survival. DGCR2 (DiGeorge syndrome critical region gene 2) is a putative adhesion receptor that is expressed in the embryo during early development and is believed to play a role in the development of the nervous system (28) . Generally, mu tations in this gene are associated with DiGeorge syndrome and velocardiofacial syndrome. The manifestations of this syndrome are immune deficiencies, cardiac anomalies, renal anomalies, eye anomalies, hypoparathyroidism, skeletal defects, and de velopmental delay (29) . Recently, additional reports have asso ciated this gene with schizophrenia and shown it to be a novel marker for pancreatic beta cellspecific proteins (30) . Thus far, there has been no report about the relationship between DGCR2 and cancer biology. In the present study, we showed that DGCR2 expression is associated with survival in MIBC. DGCR2 is likely to be associated with neuroendocrine differentiation of bladder tumors, which would mean it could be associated with poor prognosis in cancer patients. Interestingly, the present study is the first to examine the relationship between DGCR2 and sur vival in cancer patients.
Taken together, USP 18 and DGCR2 are associated with sur vival in cancer patients. Our results show that these two genes could be important prognostic markers in MIBC. Further stud ies, including a functional study, are necessary to consolidate these results.
In conclusion, decreased expressions of USP18 and DGCR2 were significantly associated with a longer rate of cancerspe cific survival, and also the combination of these two genes was correlated with longer survival rates in MIBC. Thus, the combi nation of USP18 and DGCR2 expression is a reliable predictor for cancerspecific survival in MIBC.
